File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1200/JCO.2012.47.4007
- Scopus: eid_2-s2.0-84891554529
- PMID: 24043749
- WOS: WOS:000330540400015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation
Title | Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation |
---|---|
Authors | |
Issue Date | 2013 |
Citation | Journal of Clinical Oncology, 2013, v. 31, n. 30, p. 3782-3790 How to Cite? |
Abstract | © 2013 by American Society of Clinical Oncology. Purpose: Killer-cell immunoglobulin-like receptors (KIRs) that regulate natural-killer cells are highly polymorphic. Some KIR2DL1 alleles encode receptors that have stronger signaling function than others. We tested the hypothesis that the clinical outcomes of allogeneic hematopoietic stem-cell transplantation (HSCT) could be affected by donor KIR2DL1 polymorphism. Patients and Methods: All 313 pediatric patients received allogeneic HSCT at a single institution. Donor KIR2DL1 functional allele typing was retrospectively performed using single nucleotide polymorphism assay. Results: Patients who received a donor graft containing the functionally stronger KIR2DL1 allele with arginine at amino acid position 245 (KIR2DL1-R245) had better survival (P = .0004) and lower cumulative incidence of disease progression (P = .001) than those patients who received a donor graft that contained only the functionally weaker KIR2DL1 allele with cysteine at the same position (KIR2DL1-C245). The effect of KIR2DL1 allelic polymorphism was similar in patients with acute myeloid leukemia or acute lymphoblastic leukemia among all allele groups (P ≥ .71). Patients who received a KIR2DL1-R245-positive graft with HLA-C receptor-ligand mismatch had the best survival (P = .00003) and lowest risk of leukemia progression (P = .0005) compared with those who received a KIR2DL1-C245 homozygous graft. Conclusion: Donor KIR2DL1 allelic polymorphism affects recipient outcomes after allogeneic HSCT. These findings have substantial implications for prognostication and donor selection. |
Persistent Identifier | http://hdl.handle.net/10722/294470 |
ISSN | 2023 Impact Factor: 42.1 2023 SCImago Journal Rankings: 10.639 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bari, Rafijul | - |
dc.contributor.author | Rujkijyanont, Piya | - |
dc.contributor.author | Sullivan, Erin | - |
dc.contributor.author | Kang, Guolian | - |
dc.contributor.author | Turner, Victoria | - |
dc.contributor.author | Gan, Kwan | - |
dc.contributor.author | Leung, Wing | - |
dc.date.accessioned | 2020-12-03T08:22:48Z | - |
dc.date.available | 2020-12-03T08:22:48Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Journal of Clinical Oncology, 2013, v. 31, n. 30, p. 3782-3790 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | http://hdl.handle.net/10722/294470 | - |
dc.description.abstract | © 2013 by American Society of Clinical Oncology. Purpose: Killer-cell immunoglobulin-like receptors (KIRs) that regulate natural-killer cells are highly polymorphic. Some KIR2DL1 alleles encode receptors that have stronger signaling function than others. We tested the hypothesis that the clinical outcomes of allogeneic hematopoietic stem-cell transplantation (HSCT) could be affected by donor KIR2DL1 polymorphism. Patients and Methods: All 313 pediatric patients received allogeneic HSCT at a single institution. Donor KIR2DL1 functional allele typing was retrospectively performed using single nucleotide polymorphism assay. Results: Patients who received a donor graft containing the functionally stronger KIR2DL1 allele with arginine at amino acid position 245 (KIR2DL1-R245) had better survival (P = .0004) and lower cumulative incidence of disease progression (P = .001) than those patients who received a donor graft that contained only the functionally weaker KIR2DL1 allele with cysteine at the same position (KIR2DL1-C245). The effect of KIR2DL1 allelic polymorphism was similar in patients with acute myeloid leukemia or acute lymphoblastic leukemia among all allele groups (P ≥ .71). Patients who received a KIR2DL1-R245-positive graft with HLA-C receptor-ligand mismatch had the best survival (P = .00003) and lowest risk of leukemia progression (P = .0005) compared with those who received a KIR2DL1-C245 homozygous graft. Conclusion: Donor KIR2DL1 allelic polymorphism affects recipient outcomes after allogeneic HSCT. These findings have substantial implications for prognostication and donor selection. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of Clinical Oncology | - |
dc.title | Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1200/JCO.2012.47.4007 | - |
dc.identifier.pmid | 24043749 | - |
dc.identifier.pmcid | PMC3795888 | - |
dc.identifier.scopus | eid_2-s2.0-84891554529 | - |
dc.identifier.volume | 31 | - |
dc.identifier.issue | 30 | - |
dc.identifier.spage | 3782 | - |
dc.identifier.epage | 3790 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.isi | WOS:000330540400015 | - |
dc.identifier.issnl | 0732-183X | - |